The most highly calibrated Cancer-Profile and lmmune-Spectrurn Blood Test
simple questions, concrete answers by Dietmar Schildwaechter, M.D., Ph.D.
Chief Medical Investigator
How can I know for sure if I have cancer?
How will I know if I am improving during treatment?
“Is there a reliable scientific test that tells me whether I have no cancer risk right now and can this test tell me whether I am out of danger?•
Yes, this is one of the features of this test. If anyone in your family had or has cancer, statistically increasing cancer risk, all relatives can benefit from this test.
“What about the cancer patient who was diagnosed some time ago, had perhaps Surgery or Chemotherapy or Radiation, or any combination and was told that he is free of cancer. Is he really ok?•
They may be, but no Scan, or MRI, or X-ray can tell for sure. These tests measure a “status quo” at the time they were taken. They never really tell of all important functional dynamics and whether an individual still has existing primary cancer activity, new flare-up or metastatic activity and tendency for cancer to spread to other organs until a recurrence is finally determined by a doctor.
“Can this test tell me the real situation, whether I am out of danger, or whether there still is activity so I can do something about bringing it under control?
Absolutely. This is yet another feature of this highly calibrated test.
“My doctor told me I am in remission. What does this mean?•
An individual with cancer, regardless at what stage of disease, is in remission when there is no primary and no metastatic activity and definitely no more progression of disease. This test profile with its sophisticated calibration can ascertain when you are in remission and out of danger.
“I am and/or was treated with toxic therapies that severely depressed my immune-system. Can this test tell me what the status of my immune-system is at this time?•
Yes. Your immune-profile is a very important part of this test. We are now aware of the importance of our immune-system and the role it plays in protecting us from disease.
The interpretation of your test results will tell you where you stand with your immune-defense situation at this time.
“If I do have a risk to develop cancer within a period of one to two years can I reverse this risk?
Yes, if your immune system is low, we can recommend the necessary steps to strengthen it. In 1977 scientists established with statistically significant correlation that cancer is a preventable disease.
“Why was this important finding suppressed?•
The answer may lie in the documentable fact that cancer is one of the highest profit-makers for pharmaceutical giants and institutional medicine.
Dietmar Schildwaechter, M.D., Ph.D., of Sovereign Consultants, International and Chief Medical Investigator of this project, brings thirty-six years of knowledge and expertise in preventive medicine, early cancer detection, therapy response and guidance to the individual interpretation of each test result.
CANCER and IMMUNE PROFILE TEST
In order to establish a baseline of health and to track progress through the treatment process, a blood test is available which will indicate the presence of primary and metastatic cancer activity, liver function and immune function.
This blood test identifies and quantifies in a highly calibrated, manually conducted test five significant markers, the HCG (human chorionic gonadotropic hormone) by the HCG-beta chain test, PHI (phosphohexose isomerase), the key enzyme in glycolisis which is greatly increased in cancer cell lines, GGTP for liver function, CEA (carcinoembryonic antigen) and DHEA-S.
The FDA requires an adequate means to monitor and track progression or regression during clinical use of an unapproved substance within the scope of the Institutional Review Board. Beyond these requirements the test allows the following:
- For Prevention of disease:
- Establish an individual’s health baseline.
- Determine an individual’s immune defense status.
- In established disease:
- Determine activity status, such as primary and secondary in malignant diseases not possible with status quo type scans or MRis, thus allowing:
2. Exact monitoring of response to whatever treatment chosen by treating physician and/or patron, conventional as well as unconventional.
- permits exact and scientific determination of remission in a patron.
- Establishes cures over longer period interval testing.
- Thus preventing recurrence or relapse of disease. C. For Scientific Clinical Studies and Trials
- Eliminates double blind etc., studies with high degree of inaccuracies (certainlyfrom a true epidemiological scrutiny).
- Eliminates randomized trials.
- Provides early risk factors for malignancies as a true prevention, therefore, complements cancer-search at too late a (clinical) stage with reduced survival chances (Mammography, Colonoscopy, etc.).
- Provides exact clinical-biochemical parameter results for effectiveness of new substances.
- In conjunction with unconventional medical practices.
- Complements Gaston Naessens’ Somatoscopic diagnosis
- Monitors effect of Cell-Milieu-Medicine, fetal tissue therapy, bio-electronic and homeopathic approaches.
Dr. Nieper compares the immune system with the army (which calls out the reserves when there is danger), and the anti cancer surveillance system with the police whose strength is essentially fixed.
The latter system includes mechanisms for gene repair, and certain steroids such as turnosteron and DHEA. Approximately 60% of all people have sufficient DHEA in their blood to be protected from cancer. Of the remaining 40% about half will develop hidden cancer but not die from it while the rest (20%) will die of diagnosed cancer.
A lack of DHEA has been correlated with peculiarities of the person’s character– non aggressive, amiable, easily depressed and indecisive.
DHEA-S is produced in the adrenal glands and circulates in the body as DHEA sulfate. A special activation factor, (which possibly is produced in the pineal gland or the thymus gland or the small intestines) changes DHEA-S into free DHEA.
DHEA paralyzes an enzyme (glucose-g-phosphate dehydrogenase) which is of primary importance to the action of cancer cells. This drastically reduces the vitality of the cancer cell and makes it possible for lymphocytes and other white blood cells to overcome the cancer cell.
Dr. Nieper found that during the course of disease, there is a tendency for the DHEA level to gradually decrease, sometimes to values less than 0.1 (100 nano-grams per milliliter). The cancer patient then does not have sufficient starting material to form free DHEA.
There are a number of drugs whose side effects are to cause the level of DHEA-S to drop. Most prominent are the clofibrates that are used to reduce lipid levels. A correlation has been found between higher cholesterol levels in the blood and lower frequency of cancer–if accompanied by higher values of DHEA.
DHEA was isolated by the German Nobelist Butenandt in 1934 and analyzed by the German chemist and Nobelist Windaus. However, the credit for having identified it as an important pillar of our anticancer surveillance system goes to Arthur Schwartz and his coworkers at Temple University in Philadelphia.
A summary of Dr. Hans Neiper’s discussion of DHEA from “Revolution in Medicine and Health,” November 1958.
HCG (Human Chorionic Gonadotropic hormone)
Radioimmunoassay for the HCG-Beta-chain allows the quantitation of minute amounts of human choironic gonadotropic hormone even in the presence of LH, FSH and TSH. The obvious value is the detection of pregnancy within 2-3 days after conception, detection of microabortion and detection and follow-up of HCG-secreting tumors.
Teratoma, hydatidiform mole and choriocarcinomas in the uterus, ovaries, testes, mediastinum, pineal and pituitary glands, stomach, lungs, esophagus and bladder have long been recognized as trophoblastic HCG-secreting tumors. However, HCG-B has been found in patients with practically all types of malignancies where trophoblasts were not expected:
1) testicular, nontrophoblastic gastrointestinal: carcinoid, colonic/rectal, gastric, pancreatic, small intestinal
2) hematopoietic: leukemia, all types of lymphomas, multiple myeloma
3) sarcomas: fibrosarcoma, leiomyosarcoma, osteogenic sarcoma
4) miscellaneous tumors: breast, thyroid, uterine, bladder, adrenal gland, insulinomia, pheochromocytoma
5) lung carcinoma
Indeed it seems that the HCG-secreting trophoblast may play an important role and it may be closely associated with not only embryogenesis but also carcinogenesis. As more data is becoming available, utilizing the sensitive and specific HCG-B test, it becomes evident that the frequency and types of tumors associated with HCG production are much greater than it has been suspected.
Due to the extreme sensitivity of the test (0.0025 IU/ml or about 0.2 ng/ml) it is possible to detect, without localization, ongoing malignancies at a very early stage. Once a base level has been established, a patient’s response to therapy can be monitored. The probability of detecting HCG in cancers of all types is, according to the literature surveyed, 10-100%.
The longest interval for elevated HCG-B before cancer diagnosis was 26 months.
PHI (Phospho-Hexose Isomerase or glucose phosphate isomerase)
PHI is a key enzyme in glycolysis, i.e. the main anaerobic energy generating step of glucose metabolism. Glycolysis has been observed to become greatly increased in cancer cell lines, hence the measuring of PHI became accepted as a valuable tool in the appraisal of neoplasias.
Elevated PHI levels were found in localized and metastasized cancers of the: bladder, bone, brain, breast, intestines, liver, lungs, lymphosarcoma, melanoma, mouth, head, neck, esophagus, pancreas, prostate, ovary, stomach, colon, rectum and uterus.
PHI has been shown to be elevated in more patients with neoplasia than other enzymes. However, it may not be elevated in the serum of some patients in an early state of neoplasia and indeed, it is not elevated in the serum of some patients with active diseased state. The detection of the enzyme at elevated levels may warrant a more thorough evaluation of the patient.
Once a base level has been established, PHI is a promising enzyme in following the effectiveness of therapy. When, for instance, this enzyme was monitored during treatment of breast cancer, changes in activity followed progression or regression of tumor growth and antedated other laboratory evidence by days or weeks.
It was also found to be indicative of regressions induced by steroids, radio-therapy, oophorectomy, chemotherapy, and hypophysectomy. In cases of confirmed malignancy any elevation or drop, even within the normal ranges, may be significant.
PHI may be elevated in heart, liver and skeletal muscle diseases. Preliminary data indicates that PHI levels parallel CEA results (Personal communications, Miami Heart Institute and Worthington Biochemical Corporation), however, it does not seem to be affected by smoking and it seems to reflect upon a greater variety of diseases. (The performance cost of PHI is about one-half of that of CEA.)
PHI is very abundant in the red blood cells: therefore it is imperative that the serum specimen is free from hemolysis.
References for HCG:
B.D. Weintraub and S.W. Rosen, Ectopic Production of HCS (and HGB) by Nontrophoblastic Cancers. J. Clin. Endocr., 32, 94, 1971.
- Civantos and A.M. Rywlin, Carcinomas with Trophoblastic Differentiation and Secretion of
Chorionic Gonadotropins. Cancer. 29. 789, 1972.
G.D. Braunstein, et al., Ectopic Production of ‘HCG by Neoplasms. Annals Int. Med.. 78, 39, 1973.
A.S. Rabson et al., Production of HCG in vitro by a Cell Line Derived from a Carcinoma of the Lung. J. Natl. Cancer lnst., 50, 669, 1973.
W.S. Floyd and S.L. Cohn, Gonadotropin Producing Hepatoma. Obst. Gyn, 41, 665, 1973. D.W. Gold et al., Gonadotropin-Secreting Renal Carcinoma. Cancer. 33. 1048, 1974.
D.P. Goldstein et al., The clinical Application of Specific RIA for HCG in Trophoblastic and
Nontrophoblastic tumors. Surg. Gynec. Obst.. 138, 747, 1974.
D.C. Torney et al., Biological Markers in Breast Carcinoma. Cancer. 35. 1095, 1975.
R.R. Williams et al., Tumor-Associated Antigen Levels Antedating the Diagnosis of Cancer in the
Framingham Study. J. Natl. Cancer lnst.. 58. 1547, 1977.
References for PHI:
- Bodansky, Serum PHI in Cancer: II. As an Index of Tumor Growth in M:etastatic Carcinoma of the Breast. Cancer, 7, 1191, 1954.0. Bodansky, Serum PHI in Cancer: Ill. As an Index of Tumor Growth in Metastatic Carcinoma of the Prostate. Cancer. 8. 1087, 1955.
M.M. Griffith and J.C. Beck, The Value of Serum PHI as an Index of Metastatic Breast Carcinoma Activity. Cancer. 16. 1032, 1963/
M.H. Gault et al., Serum Enzymes in Patients with Carcinoma of the Lung. Canada Med. Assoc. J .. 96. 87, 1967.
C.R. Ratliff et al., Serum LDH, PHI and Serological Evidence of Malignant Diseases. .Q1io…Chern., 16. 527, 1970.
C.R. Ratliff, Serum PHI: A glycolytic Enzyme for Appraising Neoplasia. 4th Ann. So. Calif. Lab. Conference, Anaheim, March 6, 1973.
Worthington Biochemical Corporation, In Case of Malignancy–PHI Monitors Therapy, 1974.
Letter from Dietmar Schildwaechter, M.D. Ph.D. to Ms. Jeanne O’Hara, Medicare regarding reimbursement for Cancer-immune profile test .
Ms. Jeanne O’Hara
MEDICARE General Delivery
Department of Benefits – Physician’s Services
P.O. Box 890089
Camphill, PA 17089-0089
Re: CA Profile and Immune -Profile clinical-biochemical parameter testing (according to Schandl and Nieper) for Us patients.
Dear Ms. O’Hara,
Pursuant to our telephone discussion yesterday, April 19, 1994, I am herewith attaching to this letter a 1 page copy of my testimony at N.I.H., since it describes in a concise way the features of this test.
The problem appears to be an unwillingness, of even first class laboratories, to go into the required, highly scientific calibration of our markers, so they become meaningful differential diagnostic values.
In today’s automated systems, clinical pathologists who indicated an interest to work with us, after learning the extent of required, qualified personnel, time and financial involvement etc., remarked “This is impractical for us” and perhaps questionable in its financial reward.
Since Dr. Emile K. Schandl, Ph.D., pioneered this profile in combining (biostatistically) overlapping markers to achieve an unsurpassed accuracy in 1977 (duly published and presented at scientific meetings), it has become the only reliable and constantly upgraded functional monitoring test.
Our high-cost (certainly for insurance carriers) Scans, MRis, or tornograms, etc. are strictly “status quo• examinations, not giving us any clue as to the functional ‘dynamics of primary or metastatic activity, when patients are truly in •remission• how their immune-defense situation is, etc. Recent (MAYO-clinic initial source) negative criticism about the value of CEA-markers* as a single monitoring test for Colon Cancer patients is a confirmation of our experience that it is very limited as a SINGLE marker!
In regard to insurance re-imbursement and payments for these profile tests, let me state that there apparently has been no problem (except with KAISER or HMO). All tests have the basic Blue Cross code number. Even European socialized medical insurance systems do re-imburse patients. Most tests are ordered by their physicians.
Samples from the U.S. and Canada are shipped daily to Germany by international air carriers. The results are being faxed to us and accordingly interpreted. The interpretation for all tests regardless from what country and whether for patients directly, referring physicians, clinics or hospitals, are done by me.
The German laboratory is one of the leading fully licensed and high caliber laboratories in Europe. My association goes back to the early seventies (70s) while I was Medical Director of the newest Cancer Rehabilitation Hospital within the German Government’s social medical system. I am still a licensed physician within the European community, but retired from the practice of medicine in the United States. Sovereign Consultants International was founded thereafter and is a Loudoun County, Virginia licensed and registered firm.
Laboratory super-bills are similar to the one’s used for procedures previously. They reflect the higher cost for sophisticated calibration methods required for accuracy and meaningful interpretation.
I hope this letter will help to establish a baseline for–at least partial re-imbursement for patients like Mrs. Thank you for your courtesy and cooperation.
Very truly yours,
Dietmar Schildwaechter, Ph.D., M.D.